Patent · US Active

Composition effective against viral conjunctivitis

US10220055B2 · kind B2 · utility

0Cited by

2References

14Claims

0Family size

Assignee

NICOX S.A. · FR

Inventors

Eva Prieschl-Grassauer · Wien, AT
Martina MOROKUTTI-KURZ · Wien, AT
Andreas Grassauer · Wien, AT
Sabine Nakowitsch · Wien, AT
Angelika Bodenteich · Plesching, AT
Marielle Konig-Schuster · Wien, AT
Christiane Koller · Seyring, AT
Frederic Pilotaz · Valbonne, FR

Key dates

Filing date	Jan 20, 2015
Grant date	Mar 5, 2019
Priority date	—
Expiry date	Jan 20, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P31/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a pharmaceutical composition for use as a medicament in the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7. The composition in its ready-for-use formulation comprises iota carrageenan as an active antiviral ingredient and is substantially free of a metal halide salt or contains no more than 0.5% w/v of a metal halide salt.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.